United Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 11,000 Shares

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 11,000 shares of the firm’s stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $436.60, for a total transaction of $4,802,600.00. Following the transaction, the executive vice president owned 36,781 shares in the company, valued at $16,058,584.60. This represents a 23.02% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

United Therapeutics Trading Up 2.2%

United Therapeutics stock opened at $453.07 on Friday. The company has a market capitalization of $20.44 billion, a P/E ratio of 17.68, a P/E/G ratio of 6.76 and a beta of 0.66. The firm’s fifty day simple moving average is $356.31 and its 200-day simple moving average is $319.01. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $455.12.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). The business had revenue of $798.60 million for the quarter, compared to the consensus estimate of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The firm’s revenue for the quarter was up 11.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $5.85 EPS. On average, equities research analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Institutional Trading of United Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of UTHR. Norges Bank acquired a new stake in United Therapeutics in the 2nd quarter worth $136,453,000. Invesco Ltd. boosted its position in shares of United Therapeutics by 90.2% during the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after acquiring an additional 419,588 shares in the last quarter. AQR Capital Management LLC boosted its position in shares of United Therapeutics by 40.1% during the 2nd quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock valued at $362,876,000 after acquiring an additional 364,713 shares in the last quarter. Vaughan Nelson Investment Management L.P. acquired a new stake in shares of United Therapeutics during the 1st quarter valued at about $101,354,000. Finally, Nuveen LLC acquired a new stake in shares of United Therapeutics during the 1st quarter valued at about $83,533,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. HC Wainwright raised their target price on shares of United Therapeutics from $400.00 to $500.00 and gave the company a “buy” rating in a research note on Friday, September 5th. JPMorgan Chase & Co. lowered their target price on shares of United Therapeutics from $350.00 to $330.00 and set an “overweight” rating on the stock in a research note on Tuesday, July 8th. Weiss Ratings reiterated a “hold (c+)” rating on shares of United Therapeutics in a research note on Saturday, September 27th. Bank of America raised their target price on shares of United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a research note on Tuesday, September 2nd. Finally, Royal Bank Of Canada assumed coverage on shares of United Therapeutics in a research note on Friday, September 26th. They issued an “outperform” rating and a $569.00 target price on the stock. Ten investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $449.57.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.